GSK Stock Analysis: GSK | NYSE

Drug Manufacturers - General | NYSE, USA | Market Cap: 101.126m USD | 12M Return: 6.9% | US37733W2044 | Charts, Fundamentals & Technical Analysis

Vaccines, Specialty Medicines, General Medicines, Oral Therapies
Total Rating 50
Safety 63
Buy Signal -0.80
Pharmaceuticals
Sub-Industry Rotation: +7.8
Market Cap: 101B
Avg Turnover: 174M
Risk 3d forecast
Volatility25.1%
VaR 5th Pctl4.22%
VaR vs Median2.30%
Reward TTM
Sharpe Ratio0.23
Rel. Str. IBD29.5
Rel. Str. Peer Group31.8 pctl
Character TTM
Beta0.161
Beta Downside-0.058
Hurst Exponent0.634
Choppyness79.9%
Drawdowns 3y
Max DD28.46%
CAGR/Max DD0.51
CAGR/Mean DD1.42
EPS (Earnings per Share) EPS (Earnings per Share) of GSK over the last years for every Quarter: "2021-09": 1.26, "2021-12": 0.87, "2022-03": 1.03, "2022-06": 0.87, "2022-09": 1.07, "2022-12": 0.64, "2023-03": 0.92, "2023-06": 1, "2023-09": 1.22, "2023-12": 0.73, "2024-03": 1.08, "2024-06": 1.11, "2024-09": 1.29, "2024-12": 0.58, "2025-03": 1.2, "2025-06": 1.24, "2025-09": 1.46, "2025-12": 0.7, "2026-03": 1.26, "2026-06": 1.36, "2026-09": 1.47,
EPS CAGR: 7.96%
EPS Trend: 96.7%
Last SUE: 1.69
Qual. Beats: 11
Revenue Revenue of GSK over the last years for every Quarter: 2021-09: 6627, 2021-12: 9527, 2022-03: 7190, 2022-06: 6929, 2022-09: 7829, 2022-12: 7376, 2023-03: 6951, 2023-06: 7178, 2023-09: 8147, 2023-12: 8052, 2024-03: 7363, 2024-06: 7884, 2024-09: 8012, 2024-12: 8117, 2025-03: 7516, 2025-06: 7986, 2025-09: 8547, 2025-12: 8618, 2026-03: 7629, 2026-06: 8409, 2026-09: 8817.017071,
Rev. CAGR: 3.36%
Rev. Trend: 97.5%
Last SUE: -0.02
Qual. Beats: 0

Warnings

Choppy
Below Avwap Earnings
Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 11.9 years of data, until 10/2026

Jan +1.7% 39
Feb -0.2% 0
Mar +0.9% 28
Apr +1.0% 4
May +0.4% 4
Jun -1.3% 14
Jul -1.0% 4
Aug -1.1% 4
Sep -3.9% 14
Oct -0.7% 0
Nov -1.8% 9
Dec +0.4% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.

Description: GSK GSK

GSK plc is a global pharmaceutical company headquartered in London, United Kingdom, that operates across two main segments: Commercial Operations and Total R&D. The company researches, develops, and manufactures a broad portfolio of vaccines, specialty medicines, and general medicines aimed at preventing and treating disease in markets including the UK, the US, and internationally. Its specialty medicines focus on oncology, respiratory/immunology, inflammation, and inhaled therapies for conditions such as HIV, lupus, ovarian cancer, and endometrial cancer. Its vaccine portfolio covers a wide range of diseases including Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, HPV, and Pneumonia, while its general medicines address asthma, COPD, bacterial infections, and inflammatory skin conditions.

The company also pursues discovery and commercialization of oral small molecule therapies in oncology and inflammatory diseases, and maintains multiple R&D collaborations, including partnerships with CureVac on mRNA vaccines, Engitix Ltd on liver fibrosis targets, and AN2 Therapeutics on tuberculosis therapies. Originally founded in 1715, the company was known as GlaxoSmithKline plc until rebranding to GSK plc in May 2022. As a large-cap pharmaceutical issuer listed on the NYSE, GSK operates within a sector characterized by long product development cycles, extensive regulatory oversight, and reliance on patent-protected specialty drugs alongside established vaccine franchises.

Headlines to Watch Out For
  • Shingrix vaccine sales growth drives specialty medicines revenue
  • Oncology pipeline readouts from CureVac mRNA collaboration advance
  • HIV and respiratory drug pricing faces US regulatory pressure
Piotroski VR-10 (Strict) 7.0
Net Income: 4.34b TTM > 0 and > 6% of Revenue
FCF/TA: 0.09 > 0.02 and ΔFCF/TA 2.20 > 1.0
NWC/Revenue: -8.50% < 20% (prev -14.62%; Δ 6.12% < -1%)
CFO/TA 0.12 > 3% & CFO 8.50b > Net Income 4.34b
Net Debt (21.7b) to EBITDA (8.73b): 2.49 < 3
Current Ratio: 0.86 > 1.5 & < 3
Outstanding Shares: last quarter (2.04b) vs 12m ago -0.71% < -2%
Gross Margin: 72.96% > 18% (prev 72.27%; Δ 0.69% > 0.5%)
Asset Turnover: 43.26% > 50% (prev 38.95%; Δ 4.31% > 0%)
Interest Coverage Ratio: 8.81 > 6 (EBIT TTM 6.52b / Interest Expense TTM 740.3m)
Altman Z'' 1.24
A: -0.04 (Total Current Assets 18.0b - Total Current Liabilities 20.9b) / Total Assets 72.2b
B: 0.17 (Retained Earnings 12.5b / Total Assets 72.2b)
C: 0.08 (EBIT TTM 6.52b / Avg Total Assets 77.4b)
D: 0.35 (Book Value of Equity 18.9b / Total Liabilities 53.7b)
Altman-Z'' = 1.24 = BB
Beneish M -3.16
DSRI: 0.74 (Receivables 8.58b/11.2b, Revenue 33.5b/32.2b)
GMI: 0.99 (GM 72.27% / 72.96%)
AQI: 1.12 (AQ_t 0.61 / AQ_t-1 0.54)
SGI: 1.04 (Revenue 33.5b / 32.2b)
TATA: -0.06 (NI 4.34b - CFO 8.50b) / TA 72.2b)
Beneish M = -3.16 (Cap -4..+1) = AA
What is the price of GSK shares?

As of November 20, 2026, the stock is trading at USD 47.82 with a total of 3,333,860 shares traded. Over the past week, the price has changed by -4.72%, over one month by -2.44%, over three months by -8.75% and over the past year by +6.88%.

Current recommended Stop Loss: 46.30 (which is 3.2% or 1.3 ATR below the current price).

Is GSK a buy, sell or hold?

GSK has received a consensus analysts rating of 3.33. Therefore, it is recommended to hold GSK.

  • StrongBuy: 2
  • Buy: 1
  • Hold: 5
  • Sell: 0
  • StrongSell: 1

What are the forecasts/targets for the GSK price?
Analysts Target Price 59.1 23.6%
GSK (GSK) - Fundamental Data Overview as of 17 November 2026
Market Cap USD = 101b (101b USD * 1.0 USD.USD)
Market Cap GBP = 76.9b (101b USD * 0.76063 USD.GBP)
P/E Trailing = 17.5784
P/E Forward = 10.02
P/S = 3.0148
P/B = 4.0617
P/EG = 6.4654
Revenue TTM = 33.5b GBP
EBIT TTM = 6.52b GBP
EBITDA TTM = 8.73b GBP
Long Term Debt = 14.0b GBP (from longTermDebt, last fiscal year)
Short Term Debt = 2.01b GBP (from shortTermDebt, last quarter)
Debt = 24.7b GBP (from shortLongTermDebtTotal, last quarter) + Leases 830.0m
Net Debt = 21.7b GBP (calculated: Debt 24.7b - CCE 2.98b)
Enterprise Value = 98.6b GBP (76.9b + Debt 24.7b - CCE 2.98b)
Interest Coverage Ratio = 8.81 (Ebit TTM 6.52b / Interest Expense TTM 740.3m)
EV/FCF = 14.52x (Enterprise Value 98.6b / FCF TTM 6.79b)
FCF Yield = 6.89% (FCF TTM 6.79b / Enterprise Value 98.6b)
FCF Margin = 20.30% (FCF TTM 6.79b / Revenue TTM 33.5b)
Net Margin = 12.96% (Net Income TTM 4.34b / Revenue TTM 33.5b)
Gross Margin = 72.96% ((Revenue TTM 33.5b - Cost of Revenue TTM 9.05b) / Revenue TTM)
Gross Margin QoQ = 74.46% (prev 73.05%)
Tobins Q-Ratio = 1.37 (Enterprise Value 98.6b / Total Assets 72.2b)
Interest Expense / Debt = 3.00% (Interest Expense 740.3m / Debt 24.7b)
Taxrate = 10.42% (559.2m / 5.37b)
NOPAT = 5.84b (EBIT 6.52b * (1 - 10.42%))
Current Ratio = 0.86 (Total Current Assets 18.0b / Total Current Liabilities 20.9b)
Debt / Equity = 1.31 (Debt 24.7b / totalStockholderEquity, last quarter 18.9b)
Debt / EBITDA = 2.49 (Net Debt 21.7b / EBITDA 8.73b)
Debt / FCF = 3.20 (Net Debt 21.7b / FCF TTM 6.79b)
Total Stockholder Equity = 19.1b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.61% (Net Income 4.34b / Total Assets 72.2b)
RoE = 22.74% (Net Income TTM 4.34b / Total Stockholder Equity 19.1b)
RoCE = 19.70% (EBIT 6.52b / Capital Employed (Equity 19.1b + L.T.Debt 14.0b))
RoIC = 11.31% (NOPAT 5.84b / Invested Capital 51.7b)
WACC = 5.34% (E(76.9b)/V(102b) * Re(6.19%) + D(24.7b)/V(102b) * Rd(3.00%) * (1-Tc(0.10)))
Discount Rate = 6.19% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -69.22 | Cagr: -0.53%
[DCF] Terminal Value 77.84% ; FCFF base≈6.46b ; Y1≈7.35b ; Y5≈10.6b
[DCF] Fair Price = 68.97 (EV 160b - Net Debt 21.7b = Equity 138b / Shares 2.00b; r=8.35% [WACC [floored]]; 5y FCF grow 14.13% → 2.50% )
EPS Correlation: 96.67 | EPS CAGR: 7.96% | SUE: 1.69 | # QB: 11
Revenue Correlation: 97.47 | Revenue CAGR: 3.36% | SUE: -0.02 | # QB: 0
EPS current Quarter (2027-03-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=4.76 | Chg30d=-0.73% | Revisions=+0% | GrowthEPS=+1.1% | GrowthRev=+3.6%
EPS next Year (2027-12-31): EPS=4.96 | Chg30d=-1.19% | Revisions=-38% | GrowthEPS=+4.1% | GrowthRev=+4.3%
[Analyst] Revisions Ratio: -30% (up=2, down=5)